Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3572)
All Articles published online
|
May 21, 2008 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lodato F, Azzaroli F, Girolamo MD, Feletti V, Cecinato P, Lisotti A, Festi D, Roda E, Mazzella G. Proton pump inhibitors in cirrhosis: Tradition or evidence based practice? World J Gastroenterol 2008; 14(19): 2980-2985 [PMID: 18494046 DOI: 10.3748/wjg.14.2980] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i19/2980.htm |
| Number | Citing Articles |
| 1 |
Kristen Logan, Chanjuan Shi. Clinicopathologic features of non–type 1/2 gastric neuroendocrine tumors and their associated mucosal changes. American Journal of Clinical Pathology 2023; 160(2): 130 doi: 10.1093/ajcp/aqad021
|
| 2 |
Shih-Cheng Yang, Keng-Liang Wu, Jing-Hung Wang, Chen-Hsiang Lee, Yuan-Hung Kuo, Wei-Chen Tai, Chien-Hung Chen, Shue-Shian Chiou, Sheng-Nan Lu, Tsung-Hui Hu, Chi-Sin Changchien, Seng-Kee Chuah. The effect of systemic antibiotic prophylaxis for cirrhotic patients with peptic ulcer bleeding after endoscopic interventions. Hepatology International 2013; 7(1): 257 doi: 10.1007/s12072-012-9378-z
|
| 3 |
Moloud Balafar, Morteza Ghojazadeh, Kavous Shahsavarinia, Zahra Parsian, Saba Hamedani, Hassan Soleimanpour. Association Between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis or Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and Meta-analysis. Hepatitis Monthly 2023; 23(1) doi: 10.5812/hepatmon-132642
|
| 4 |
Carmelo Scarpignato, Luigi Gatta, Angelo Zullo, Corrado Blandizzi. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine 2016; 14(1) doi: 10.1186/s12916-016-0718-z
|
| 5 |
Jee Hye Kwon, Seong‐Joon Koh, Won Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Jong Pil Im, Yoon Jun Kim, Joo Sung Kim, Jung‐Hwan Yoon, Hyo‐Suk Lee, Hyun Chae Jung. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. Journal of Gastroenterology and Hepatology 2014; 29(4): 775 doi: 10.1111/jgh.12426
|
| 6 |
Raphaël Eftimie Spitz, Stefan Lucian Popa, Simona Grad, Dan Lucian Dumitrascu, Abdulrahman Ismaiel, Teodora Surdea-Blaga. The Use of Proton Pump Inhibitors in Patients with Liver Cirrhosis: Real Life Experience. Journal of Clinical Medicine 2024; 13(17): 5155 doi: 10.3390/jcm13175155
|
| 7 |
Manuela Merli, Cristina Lucidi, Vincenza Di Gregorio, Valerio Giannelli, Michela Giusto, Giancarlo Ceccarelli, Oliviero Riggio, Mario Venditti. The chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver International 2015; 35(2): 362 doi: 10.1111/liv.12593
|
| 8 |
Shih-Cheng Yang, Jen-Chieh Chen, Wei-Chen Tai, Cheng-Kun Wu, Chen-Hsiang Lee, Keng-Liang Wu, Yi-Chun Chiu, Jing-Houng Wang, Sheng-Nan Lu, Seng-Kee Chuah, Georgina L. Hold. The Influential Roles of Antibiotics Prophylaxis in Cirrhotic Patients with Peptic Ulcer Bleeding after Initial Endoscopic Treatments. PLoS ONE 2014; 9(5): e96394 doi: 10.1371/journal.pone.0096394
|
| 9 |
Ting Yu, Yurong Tang, Liuqin Jiang, Yongping Zheng, Wenjie Xiong, Lin Lin. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. Digestive and Liver Disease 2016; 48(4): 353 doi: 10.1016/j.dld.2015.12.009
|
| 10 |
H. L. Cole, S. Pennycook, P. C. Hayes. The impact of proton pump inhibitor therapy on patients with liver disease. Alimentary Pharmacology & Therapeutics 2016; 44(11-12): 1213 doi: 10.1111/apt.13827
|
| 11 |
Chia-Fen Tsai, Mu-Hong Chen, Yen-Po Wang, Chi-Jen Chu, Yi-Hsiang Huang, Han-Chieh Lin, Ming-Chih Hou, Fa-Yauh Lee, Tung-Ping Su, Ching-Liang Lu. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology 2017; 152(1): 134 doi: 10.1053/j.gastro.2016.09.007
|
| 12 |
Leon Fisher, Alexander Fisher. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clinical Drug Investigation 2017; 37(7): 587 doi: 10.1007/s40261-017-0519-y
|
| 13 |
Alice Capogrosso Sansone, Irma Convertino, Maria Teresa Galiulo, Stefano Salvadori, Stefania Pieroni, Tamara Knezevic, Stefania Mantarro, Alessandra Marino, Manfred Hauben, Corrado Blandizzi, Marco Tuccori. Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. Drug Safety 2017; 40(10): 895 doi: 10.1007/s40264-017-0564-8
|
| 14 |
Shiyan Wu, Lu Li, Heng Xi, Xiaoping Wu, Yumei He, Xiaobin Sun, Liping Wu. Bibliometrics and knowledge mapping of the pathogenesis of hepatic encephalopathy in patients with liver cirrhosis. Heliyon 2024; 10(15): e34330 doi: 10.1016/j.heliyon.2024.e34330
|
| 15 |
Helen Ngo, Raymund Gantioque. Predictors of Spontaneous Bacterial Peritonitis (SBP) in Liver Cirrhosis: Current Knowledge and Future Frontiers. Open Journal of Gastroenterology 2017; 7(12): 297 doi: 10.4236/ojgas.2017.712031
|
| 16 |
Yoshimi Yukawa‐Muto, Tomonori Kamiya, Hideki Fujii, Hiroshi Mori, Atsushi Toyoda, Ikuya Sato, Yusuke Konishi, Akiyoshi Hirayama, Eiji Hara, Shinji Fukuda, Norifumi Kawada, Naoko Ohtani. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. Hepatology Communications 2022; 6(8): 2090 doi: 10.1002/hep4.1954
|
| 17 |
Jasmohan S Bajaj, Yelena Zadvornova, Douglas M Heuman, Muhammad Hafeezullah, Raymond G Hoffmann, Arun J Sanyal, Kia Saeian. Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites. The American Journal of Gastroenterology 2009; 104(5): 1130 doi: 10.1038/ajg.2009.80
|
| 18 |
David Kockerling, Rooshi Nathwani, Roberta Forlano, Pinelopi Manousou, Benjamin H Mullish, Ameet Dhar. Current and future pharmacological therapies for managing cirrhosis and its complications. World Journal of Gastroenterology 2019; 25(8): 888-908 doi: 10.3748/wjg.v25.i8.888
|
| 19 |
Maria Papp, Nora Sipeki, Zsuzsanna Vitalis, Tamas Tornai, Istvan Altorjay, Istvan Tornai, Miklos Udvardy, Kai Fechner, Silvia Jacobsen, Bianca Teegen, Andrea Sumegi, Gabor Veres, Peter Laszlo Lakatos, Janos Kappelmayer, Peter Antal-Szalmas. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis. Journal of Hepatology 2013; 59(3): 457 doi: 10.1016/j.jhep.2013.04.018
|
| 20 |
Maria Pleguezuelo, Jose Manuel Benitez, Juan Jurado, Jose Luis Montero, Manuel De la Mata. Diagnosis and management of bacterial infections in decompensated cirrhosis. World Journal of Hepatology 2013; 5(1): 16-25 doi: 10.4254/wjh.v5.i1.16
|
| 21 |
V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, A. A. Sheptulin, V. I. Simanenkov, T. L. Lapina, I. B. Khlynov, N. N. Dekhnich, O. D. Lopina, O. P. Alekseeva, N. V. Korochanskaya, M. F. Osipenko, P. V. Pavlov, S. S. Pirogov, G. N. Tarasova, Yu. P. Uspenskiy, D. N. Andreev, D. E. Rumyantseva. Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week). Russian Journal of Gastroenterology, Hepatology, Coloproctology 2020; 30(6): 7 doi: 10.22416/1382-4376-2020-30-6-7-18
|
| 22 |
Tricia E. Brentjens, Ryan Chadha. Anesthesia for the Patient with Concomitant Hepatic and Renal Impairment. Anesthesiology Clinics 2016; 34(4): 645 doi: 10.1016/j.anclin.2016.06.002
|
| 23 |
Shuichi Matsumoto, Naoho Takizawa, Yasunari Kaneyama, Hitoki Miyai, Nobuhiro Kodama, Sunao Matsubayashi. Relationship between proton pump inhibitor therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Kanzo 2014; 55(9): 530 doi: 10.2957/kanzo.55.530
|
| 24 |
Marie de Vos, Bénédicte De Vroey, Béatrice Garcia Garcia, Clothilde Roy, François Kidd, Jean Henrion, Pierre Deltenre. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver International 2013; 33(9): 1316 doi: 10.1111/liv.12210
|
| 25 |
Elaine A. G. Lo, Kyle J. Wilby, Mary H. H. Ensom. Use of Proton Pump Inhibitors in the Management of Gastroesophageal Varices. Annals of Pharmacotherapy 2015; 49(2): 207 doi: 10.1177/1060028014559244
|
| 26 |
G. Trikudanathan, J. Israel, J. Cappa, D. M. O’Sullivan. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. International Journal of Clinical Practice 2011; 65(6): 674 doi: 10.1111/j.1742-1241.2011.02650.x
|
| 27 |
D. Ahrens, G. Behrens, W. Himmel, M. M. Kochen, J.-F. Chenot. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. International Journal of Clinical Practice 2012; 66(8): 767 doi: 10.1111/j.1742-1241.2012.02973.x
|
| 28 |
Yasir Al-Azzawi, Yasir Al-Abboodi, Matthew Fasullo, Tarek Najuib. The Morbidity and Mortality of Laparoscopic Appendectomy in Patients with Cirrhosis. Clinical Medicine Insights: Gastroenterology 2018; 11 doi: 10.1177/1179552217746645
|
| 29 |
Tsung-Hsing Hung, Chih-Wei Tseng, Hsing-Feng Lee, Chih-Chun Tsai, Chen-Chi Tsai. Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. Annals of Hepatology 2018; 17(6): 933 doi: 10.5604/01.3001.0012.7193
|
| 30 |
Jolene F Siple, Jessica M Morey, Tracy E Gutman, Kathy L Weinberg, Peggie D Collins. Proton Pump Inhibitor Use and Association with Spontaneous Bacterial Peritonitis in Patients with Cirrhosis and Ascites. Annals of Pharmacotherapy 2012; 46(10): 1413 doi: 10.1345/aph.1R174
|
| 31 |
Ji Min Han, Jeong Yee, Yoon Sook Cho, Hye Sun Gwak. Factors Influencing Imatinib-Induced Hepatotoxicity. Cancer Research and Treatment 2020; 52(1): 181 doi: 10.4143/crt.2019.131
|
| 32 |
Chalermrat Bunchorntavakul, Naichaya Chamroonkul, Disaya Chavalitdhamrong. Bacterial infections in cirrhosis: A critical review and practical guidance. World Journal of Hepatology 2016; 8(6): 307-321 doi: 10.4254/wjh.v8.i6.307
|
| 33 |
Cheng-Kun Wu, Chih-Ming Liang, Chien-Ning Hsu, Tsung-Hsing Hung, Lan-Ting Yuan, Seng-Howe Nguang, Jiunn-Wei Wang, Kuo-Lun Tseng, Ming-Kun Ku, Shih-Cheng Yang, Wei-Chen Tai, Chih-Wei Shih, Pin-I Hsu, Deng-Chyang Wu, Seng-Kee Chuah, John Green. The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation. PLOS ONE 2017; 12(1): e0169884 doi: 10.1371/journal.pone.0169884
|
| 34 |
A. Trifan, O. Stoica, C. Stanciu, C. Cojocariu, A.-M. Singeap, I. Girleanu, E. Miftode. Clostridium difficile infection in patients with liver disease: a review. European Journal of Clinical Microbiology & Infectious Diseases 2015; 34(12): 2313 doi: 10.1007/s10096-015-2501-z
|
| 35 |
O. D. Lopina, B. K. Nurgalieva, T. L. Lapina. Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2021; 31(4): 55 doi: 10.22416/1382-4376-2021-31-4-55-63
|
| 36 |
Paulo Carrola, Isabel Militão, José Presa. Infeções bacterianas no doente com cirrose hepática. GE Jornal Português de Gastrenterologia 2013; 20(2): 58 doi: 10.1016/j.jpg.2012.09.008
|
| 37 |
Mattias Mandorfer, Simona Bota, Philipp Schwabl, Theresa Bucsics, Nikolaus Pfisterer, Christian Summereder, Michael Hagmann, Alexander Blacky, Arnulf Ferlitsch, Wolfgang Sieghart, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger, Erica Villa. Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. PLoS ONE 2014; 9(11): e110503 doi: 10.1371/journal.pone.0110503
|
| 38 |
Seamus Hussey, Kathleen T. Kelleher, Simon C. Ling. Emergency Management of Major Upper Gastrointestinal Hemorrhage in Children. Clinical Pediatric Emergency Medicine 2010; 11(3): 207 doi: 10.1016/j.cpem.2010.06.003
|
| 39 |
Jacqueline G. O'Leary, K. Rajender Reddy, Florence Wong, Patrick S. Kamath, Heather M. Patton, Scott W. Biggins, Michael B. Fallon, Guadalupe Garcia-Tsao, Ram M. Subramanian, Raza Malik, Leroy R. Thacker, Jasmohan S. Bajaj. Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology 2015; 13(4): 753 doi: 10.1016/j.cgh.2014.07.060
|
| 40 |
Tamas Tornai, Zsuzsanna Vitalis, Nora Sipeki, Tamas Dinya, David Tornai, Peter Antal‐Szalmas, Zsolt Karanyi, Istvan Tornai, Maria Papp. Macrophage activation marker, soluble CD163, is an independent predictor of short‐term mortality in patients with cirrhosis and bacterial infection. Liver International 2016; 36(11): 1628 doi: 10.1111/liv.13133
|
| 41 |
Peter R. McNally, P. Alexander McNally. Gastrointestinal Endoscopy in the Cancer Patient. 2013; : 242 doi: 10.1002/9781118555651.ch23
|
| 42 |
Chii-Shyan Lay, Jiun-Rong Lin. Correlation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer. Journal of the Chinese Medical Association 2010; 73(4): 188 doi: 10.1016/S1726-4901(10)70039-3
|
| 43 |
Antonio Picardi, Umberto Vespasiani-Gentilucci. Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World Journal of Gastrointestinal Pharmacology and Therapeutics 2016; 7(1): 1-4 doi: 10.4292/wjgpt.v7.i1.1
|
| 44 |
Sameh A. Lashen, Mohammed M. Shamseya, Ayman M. Shamseya, Fahmy H. Hablass. Efficacy of Vonoprazan vs. Pantoprazole or Non-acid Suppression in Prevention of Post-variceal Ligation Ulcer Bleeding in Portal Hypertension: A Multi-arm Randomized Controlled Trial. Journal of Clinical and Experimental Hepatology 2023; 13(6): 962 doi: 10.1016/j.jceh.2023.05.008
|
| 45 |
Dirk Ahrens, Jean-François Chenot, Gesa Behrens, Thomas Grimmsmann, Michael M. Kochen. Appropriateness of treatment recommendations for PPI in hospital discharge letters. European Journal of Clinical Pharmacology 2010; 66(12): 1265 doi: 10.1007/s00228-010-0871-9
|
| 46 |
Jasmohan S Bajaj, Ashwin N Ananthakrishnan, Muhammad Hafeezullah, Yelena Zadvornova, Alexis Dye, Emily L McGinley, Kia Saeian, Douglas Heuman, Arun J Sanyal, Raymond G Hoffmann. Clostridium difficile Is Associated With Poor Outcomes in Patients With Cirrhosis: A National and Tertiary Center Perspective. American Journal of Gastroenterology 2010; 105(1): 106 doi: 10.1038/ajg.2009.615
|
| 47 |
Kei Morio, Michio Imamura, Yoshiiku Kawakami, Yuki Nakamura, Masahiro Hatooka, Reona Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Hiroshi Aikata, C. Nelson Hayes, Daiki Miki, Hidenori Ochi, Yoshio Katamura, Keiko Arataki, Takashi Moriya, Hiroyuki Ito, Keiji Tsuji, Hiroshi Kohno, Koji Waki, Toru Tamura, Toshio Nakamura, Kazuaki Chayama. Advanced liver fibrosis effects on the response to sofosbuvir‐based antiviral therapies for chronic hepatitis C. Journal of Medical Virology 2018; 90(12): 1834 doi: 10.1002/jmv.25267
|
| 48 |
D. K. Li, P. Yan, A‐B. Abou‐Samra, R. T. Chung, A. A. Butt. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Alimentary Pharmacology & Therapeutics 2018; 47(2): 246 doi: 10.1111/apt.14391
|
| 49 |
Saad Alhumaid, Abbas Al Mutair, Zainab Al Alawi, Abdul Rehman Zia Zaidi, Ali A. Rabaan, Alyaa Elhazmi, Awad Al-Omari. Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis. Gut Pathogens 2021; 13(1) doi: 10.1186/s13099-021-00414-8
|
| 50 |
José Alberto González-González, Diego García-Compean, Genaro Vázquez-Elizondo, Aldo Garza-Galindo, Joel Omar Jáquez-Quintana, Héctor Maldonado-Garza. Nonvariceal upper gastrointestinal bleeding in patients with liver cirrhosis. Clinical features, outcomes and predictors of in-hospital mortality. A prospective study. Annals of Hepatology 2011; 10(3): 287 doi: 10.1016/S1665-2681(19)31540-6
|
| 51 |
Fady Maher Wadea. Insights to Indications and Harm of Proton Pump Inhibitors Usage in Patients with Liver Cirrhosis. Gastroenterology & Hepatology: Open Access 2017; 7(5) doi: 10.15406/ghoa.2017.07.00250
|
| 52 |
Panayiotis D. Ziakas, Nina Joyce, Ioannis M. Zacharioudakis, Fainareti N. Zervou, Richard W. Besdine, Vincent Mor, Eleftherios Mylonakis. Prevalence and impact of Clostridium difficile infection in elderly residents of long-term care facilities, 2011. Medicine 2016; 95(31): e4187 doi: 10.1097/MD.0000000000004187
|
| 53 |
Miguel Ángel Hidalgo-Blanco, Juan Carlos Lopez-Delgado, José Antonio Sarria-Guerrero. Nutrition Therapy in Critically Ill Patients with Liver Disease: A Narrative Review. Livers 2023; 3(3): 529 doi: 10.3390/livers3030036
|
| 54 |
Tram B. Cat, Xi Liu-DeRyke. Medical Management of Variceal Hemorrhage. Critical Care Nursing Clinics of North America 2010; 22(3): 381 doi: 10.1016/j.ccell.2010.02.004
|
| 55 |
Marianne Anastasia De Roza, Lim Kai, Jia Wen Kam, Yiong Huak Chan, Andrew Kwek, Tiing Leong Ang, John Chen Hsiang. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World Journal of Gastroenterology 2019; 25(33): 4933-4944 doi: 10.3748/wjg.v25.i33.4933
|
| 56 |
Jung Hee Kim, Kyung Sook Lim, Yang Won Min, Hyuk Lee, Byung‐Hoon Min, Poong‐Lyul Rhee, Jae J Kim, Kwang Cheol Koh, Seung Woon Paik. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. Journal of Gastroenterology and Hepatology 2017; 32(5): 1064 doi: 10.1111/jgh.13637
|
| 57 |
G. Dultz, A. Piiper, S. Zeuzem, B. Kronenberger, O. Waidmann. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Alimentary Pharmacology & Therapeutics 2015; 41(5): 459 doi: 10.1111/apt.13061
|